CB2 Insights announced it has partnered with Licensed Producer, Vireo Health International Inc. to advance the proof of safety and efficacy for cannabinoid therapy as it relates to metered-dosing for patients with ailments in which cannabis-based medicine is believed to support. CB2 will oversee the protocol development and Investigational New Drug (IND) Application directly with the US Food & Drug Administration (FDA). The successful completion will position Vireo for industry leadership when it comes to cannabis-based topical medication used to treat pain. Vireo will also license the Company’s Sail technology platform for full data collection and management. Vireo is a physician-founded, science-focused vertically integrated cannabis company focused on bringing medical science and engineering effective cannabis-based medicine. Thousands of patients across seven U.S. states have used Vireo’s products for a wide range of conditions including chronic pain, cancer, epilepsy and many others as permitted under various state laws. Vireo’s line of cannabis-based topical products – currently available in Minnesota and scheduled to launch in other markets in 2020 - will be the focus of this project. CB2 Insights will manage the process of designing the protocol and working with the FDA on IND application approval.